Is this a new threat for CSL shares?

There's a new wonder drug on the scene. Should shareholders be concerned?

| More on:
Shot of a mature scientists working on a laptop in a lab.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

CSL Ltd (ASX: CSL) shares are ending the week in the red.

At the time of writing, the biotechnology giant's shares are down almost 2% to $281.78.

Why are CSL shares falling?

With no news out of the company, it isn't clear why its shares are under pressure today.

But given how some analysts believe that weight loss drugs could have a negative impact on the company's sales, it's possible that news of a new wonder drug could be weighing on sentiment.

Earlier this week, Viking Therapeutics (NASDAQ: VKTX) shares rocketed over 100% after announcing positive top-line results from its phase 2 clinical trial of VK2735.

It is a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors that is in development for the potential treatment of various metabolic disorders such as obesity.

Viking revealed that the phase 2 trial successfully achieved its primary endpoint and all secondary endpoints. Patients receiving VK2735 demonstrated statistically significant reductions in body weight compared with placebo.

Importantly, the study showed VK2735 to be safe and well tolerated with the majority of treatment emergent adverse events (TEAEs) being categorised as mild or moderate.

Is this a threat to CSL?

Opinion remains divided on whether GLP-1s are a threat to CSL and its shares. A number of analysts believe they could be due to the possible kidney benefits resulting from their use. However, CSL doesn't believe this will be the case.

As we covered here late last year, the company's CEO, Paul McKenzie, commented:

There's been a lot of talk about GLP-1s […] To give you the punchline, based on the high-level results, we do not see GLP-1s as having a material impact on the business.

This sentiment was echoed by CSL Vifor general manager, Hervé Gisserot. He said:

In our view, as already stated by Paul, the renal disease market won't be disrupted by GLP-1.

Motley Fool contributor James Mickleboro has positions in CSL. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A doctor appears shocked as he looks through binoculars on a blue background.
Healthcare Shares

3 ASX 200 healthcare stocks that could deliver big returns for investors

Analysts see a lot of value in these stocks at current levels.

Read more »

A team of people giving the thumbs up sign representing APA and Wesfarmers doing a deal to study green hydrogen transport using an APA gas pipeline
Healthcare Shares

Why are so many top fundies overweight on CSL shares?

This is a healthy opportunity, according to a number of fund managers.

Read more »

Scientist looking at a laptop thinking about the share price performance.
Share Fallers

Why did this ASX All Ords stock just crash 16%?

Investors are punishing this ASX All Ords stock on Thursday. But why?

Read more »

woman in lab coat conducting testing representing biotech
Healthcare Shares

Can the CSL share price really reach $500 in just 3 years?

Leading analysts are expecting big returns from CSL shares in the months ahead.

Read more »

Two businesspeople walk together in an office, smiling as they enjoy a good business relationship.
Healthcare Shares

Why two brokers have named this ASX 200 stock as a best buy

Investors may want to pounce on this high-quality stock before it's too late.

Read more »

A young man goes over his finances and investment portfolio at home.
Healthcare Shares

What could $5,000 invested in CSL shares become in 1 year?

Let's see what sort of returns analysts are tipping for this ASX giant.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

Why is everyone talking about Mesoblast shares?

ASX biotech share Mesoblast has been grabbing plenty of investor attention recently.

Read more »

A happy doctor in a white coat dancing due to his excitement over the EBOS acquisition
Healthcare Shares

Why the Mesoblast share price can rise another 60%

The big gains may not be over according to Bell Potter.

Read more »